AFM analysis of the multiple types of molecular interactions involved in rituximab lymphoma therapy on patient tumor cells and NK cells

Cellular Immunology

Volumn 290, Issue 2, 2014, Pages 233-244

  Li, Mi ^a,b   Xiao, Xiubin ^c   Zhang, Weijing ^c   Liu, Lianqing ^a   Xi, Ning ^a,d   Wang, Yuechao ^a  

^a SHENYANG INSTITUTE OF AUTOMATION   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^d CITY UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Antibody dependent cellular cytotoxicity; Atomic force microscopy; CD20; Fc receptor; Lymphoma; Natural killer cell

Indexed keywords

ANTINEOPLASTIC AGENT; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; FC RECEPTOR; FLUDARABINE; FLUORESCENT DYE; RITUXIMAB; DOXORUBICIN; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; PREDNISOLONE; PROTEIN; ROR1 PROTEIN; UNCLASSIFIED DRUG; VINCRISTINE; MONOCLONAL ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; ATOMIC FORCE MICROSCOPY; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; LYMPHOMA; LYMPHOMA CELL; MALE; MOLECULAR INTERACTION; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; ADULT; BONE MARROW; FLUORESCENCE MICROSCOPY; HUMAN TISSUE; IN VITRO STUDY; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; PROTEIN BINDING; TUMOR CELL; ANTIBODY AFFINITY; DRUG EFFECTS; IMMUNOLOGY; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY AFFINITY; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HUMANS; KILLER CELLS, NATURAL; LYMPHOMA; MICROSCOPY, ATOMIC FORCE; RECEPTORS, FC;

EID: 84907089061     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2014.07.003     Document Type: Article

References (59)

1. Binnig G., Quate C.F., Gerber C. Atomic force microscope. Phys. Rev. Lett. 1986, 56(9):930-933.
2. Taatjes D.J., Quinn A.S., Rand J.H., Jena B.P. Atomic force microscopy: high resolution dynamic imaging of cellular and molecular structure in health and disease. J. Cell. Physiol. 2013, 228(10):1949-1955.
3. Dupres V., Alsteens D., Andre G., Verbelen C., Dufrene Y.F. Fishing single molecules on live cells. Nano Today 2009, 4:262-268.
4. Muller D.J., Helenius J., Alsteens D., Dufrene Y.F. Force probing surfaces of living cells to molecular resolution. Nat. Chem. Biol. 2009, 5(6):383-390.
5. Alsteens D., Trabelsi H., Soumillion P., Dufrene Y.F. Multiparametric atomic force microscopy imaging of single bacteriophages extruding from living bacteria. Nat. Commun. 2013, 4:2926.
6. Zhang J., Chtcheglova L.A., Zhu R., Hinterdorfer P., Zhang B., Tang J. Nanoscale organization of human GnRH-R on human bladder cancer cells. Anal. Chem. 2014, 86(5):2458-2464.
7. Dufrene Y.F., Evans E., Engel A., Helenius J., Gaub H.E., Muller D.J. Five challenges to bringing single-molecule force spectroscopy into living cells. Nat. Methods 2011, 8(2):123-127.
8. Shi X., Zhang X., Xia T., Fang X. Living cell study at the single-molecule and single-cell levels by atomic force microscopy. Nanomedicine 2012, 7(10):1625-1637.
9. Li M., Xiao X., Liu L., Xi N., Wang Y., Dong Z., Zhang W. Atomic force microscopy study of the antigen-antibody binding force on patient cancer cells based on ROR1 fluorescence recognition. J. Mol. Recognit. 2013, 26(9):432-438.
10. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
11. Maloney D.G. Anti-CD20 antibody therapy for B-cell lymphomas. N. Engl. J. Med. 2012, 366:2008-2016.
12. Lim S.H., Beers S.A., French R.R., Johnson P.W.M., Glennie M.J., Cragg M.S. Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica 2010, 95(1):135-143.
13. Adams G.P., Weiner L.M. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 2005, 23(9):1147-1157.
14. Alduaij W., Illidge T.M. The future of anti-CD20 monoclonal antibodies: are we making progress?. Blood 2011, 117(11):2993-3001.
15. Zwick C., Murawski N., Pfreundschuh M. Rituximab in high-grade lymphoma. Semin. Hematol. 2010, 47(2):148-155.
16. Xie X.S., Yu J., Yang W.Y. Living cells as test tubes. Science 2006, 312(5771):228-230.
17. Altschuler S.J., Wu L.F. Cellular heterogeneity: do differences make a difference?. Science 2010, 141:559-563.
18. Muller D.J., Dufrene Y.F. Force nanoscopy of living cells. Curr. Biol. 2011, 21(6):R212-R216.
19. Hinterdorfer P., Dufrene Y.F. Detection and localization of single molecular recognition events using atomic force microscopy. Nat. Methods 2006, 3(5):347-355.
20. Li M., Xiao X., Zhang W., Liu L., Xi N., Wang Y. Nanoscale distribution of CD20 on B-cell lymphoma tumour cells and its potential role in the clinical efficacy of rituximab. J. Microsc. 2014, 254(1):19-30.
21. Hutter J.L., Bechhoefer J. Calibration of atomic-force microscope tips. Rev. Sci. Instrum. 1993, 64:1868-1873.
22. Uhrmacher S., Schmidt C., Erdfelder F., Poll-Wolbeck S.J., Gehrke I., Hallek M., Kreuzer K.A. Use of the receptor tyrosine kinase-like orphan receptor 1(ROR1) as a diagnostic tool in chronic lymphocytic leukemia (CLL). Leuk. Res. 2011, 35(10):1360-1366.
23. Widhopf G.F., Cui B., Ghia E.M., Chen L., Messer K., Shen Z., Briggs S.P., Croce C.M., Kipps T.J. ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 2014, 111(2):793-798.
24. Jaron-Mendelson M., et al. Dimerization of NKp46 receptor is essential for NKp46-mediated lysis: characterization of the dimerization site by epitope mapping. J. Immunol. 2012, 188(12):6165-6174.
25. Stroch C., Wang H., Bash R., Ashcroft B., Nelson J., Gruber H., Lohr D., Lindsay S.M., Hinterdorfer P. Single-molecule recognition imaging microscopy. Proc. Natl. Acad. Sci. U.S.A. 2004, 101(34):12503-12507.
26. Cai M., Zhao W., Shang X., Jiang J., Ji H., Tang Z., Wang H. Direct evidence of lipid rafts by in situ atomic force microscopy. Small 2012, 8(8):1243-1250.
27. Mselle T.F., Howell A.L., Ghosh M., Wira C.R., Sentman C.L. Human uterine natural killer cells but not blood natural killer cells inhibit human immunodeficiency virus type 1. J. Virol. 2009, 83(21):11188-11195.
28. Silva M.R.G., Hoffman R., Srour E.F., Ascensao J.L. Generation of human natural killer cells from immature progenitors does not require marrow stromal cells. Blood 1994, 84(3):841-846.
29. Santo J.P.D., Vosshenrich C.A.J. Bone marrow versus thymic pathways of natural killer cell development. Immunol. Rev. 2006, 214:35-46.
30. Li M., Liu L., Xi N., Wang Y., Xiao X., Zhang W. Nanoscale imaging and mechanical analysis of Fc receptor-mediated macrophage phagocytosis against cancer cells. Langmuir 2014, 30(6):1609-1621.
31. El-Kirat-Chatel S., Dufrene Y.F. Nanoscale imaging of the candida-macrophage interaction using correlated fluorescence-atomic force microscopy. ACS Nano 2012, 6(12):10792-10799.
32. Hailey S., Adams E., Penn R., Wong A., McLane M.A. Effect of the disintegrin eristostatin on melanoma-natural killer cell interactions. Toxicon 2013, 61:83-93.
33. Braet F., Vermijlen D., Bossuyt V., Zanger R.D., Wisse E. Early detection of cytotoxic events between hepatic natural killer cells and colon carcinoma cells as probed with the atomic force microscope. Ultramicroscopy 2001, 89(4):265-273.
34. Plodinec M., et al. The nanomechanical signature of breast cancer. Nat. Nanotechnol. 2012, 7(11):757-765.
35. Lee C.K., Wang Y.M., Huang L.S., Lin S. Atomic force microscopy: determination of unbinding force, off rate and energy barrier for protein-ligand interaction. Micron 2007, 38(5):446-461.
36. Carvalho F.A., Santos N.C. Atomic force microscopy-based force spectroscopy-biological and biomedical applications. IUBMB Life 2012, 64(6):465-472.
37. Glennie M.J., French R.R., Cragg M.S., Taylor R.P. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol. Immunol. 2007, 44(16):3823-3837.
38. Guilliams M., Bruhns P., Saeys Y., Hammad H., Lambrecht B.N. The function of Fcγ receptors in dendritic cells and macrophages. Nat. Rev. Immunol. 2014, 14(2):94-108.
39. Hinterdorfer P., Baumgartner W., Gruber H.J., Schilcher K., Schindler H. Detection and localization of individual antibody-antigen recognition events by atomic force microscopy. Proc. Natl. Acad. Sci. U.S.A. 1996, 93(8):3477-3481.
40. Shi X., Xu L., Yu J., Fang X. Study of inhibitioin effect of Herceptin on interaction between Heregulin and ErbB receptors HER3/HER2 by single-molecule force spectroscopy. Exp. Cell Res. 2009, 315(16):2847-2855.
41. Zhu R., Rupprecht A., Ebner A., Haselgrubler T., Gruber H.J., Hinterdorfer P., Pohl E.E. Mapping the nucleotide binding site of uncoupling protein 1 using atomic force microscopy. J. Am. Chem. Soc. 2013, 135(9):3640-3646.
42. Li M., Xiao X., Liu L., Xi N., Wang Y., Dong Z., Zhang W. Nanoscale mapping and organization analysis of target proteins on cancer cells from B-cell lymphoma patients. Exp. Cell Res. 2013, 319(18):2812-2821.
43. Hu Y., Ulstrup J., Zhang J., Molin S., Dupres V. Adhesive properties of staphylococcus epidermidis probed by atomic force microscopy. Phys. Chem. Chem. Phys. 2011, 13(21):9995-10003.
44. Li Y., et al. Monocyte surface expression of Fcγ receptor RI (CD64), a biomarker reflecting type-I interferon levels in systemic lupus erythematosus. Arthritis Res. Ther. 2010, 12(3):R90.
45. Lim S.H., et al. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood 2011, 118(9):2530-2540.
46. Hinterdorfer P., Garcia-Parajo M.F., Dufrene Y.F. Single-molecule imaging of cell surfaces using near-field nanoscopy. Acc. Chem. Res. 2012, 45(3):327-336.
47. Li M., Liu L., Xi N., Wang Y., Xiao X., Zhang W. Imaging and measuring the biophysical properties of Fc gamma receptors on single macrophages using atomic force microscopy. Biochem. Biophys. Res. Commun. 2013, 438(4):709-714.
48. Bippes C.A., Muller D.J. High-resolution atomic force microscopy and spectroscopy of native membrane proteins. Rep. Prog. Phys. 2011, 74(8):086601.
49. Tan L., Lin P., Chisti M.M., Rehman A., Zeng X. Real time analysis of binding between rituxima (anti-CD20 antibody) and B lymphoma cells. Anal. Chem. 2013, 85(18):8543-8551.
50. Smith M.R. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003, 22(47):7359-7368.
51. Silverman G.J., Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum. 2003, 48(6):1484-1492.
52. Galon J., Robertson M.W., Galinha A., Mazieres N., Spagnoli R., Fridman W.H., Sautes C. Affinity of the interaction between Fc gamma receptor type III (FcγRIII) and monomeric human IgG subclasses role of FcγRIII glycosylation. Eur. J. Immunol. 1997, 27(8):1928-1932.
53. Bruhns P., Iannascoli B., England P., Mancardi D.A., Fernandez N., Jorieux S., Daeron M. Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses. Blood 2009, 113(16):3716-3725.
54. Fernandez-Segura E., Garcia J.M., Lopez-Escamez J.A., Campos A. Surface expression and distribution of Fc receptor III (CD16 molecule) on human natural killer cells and polymorphonuclear neutrophils. Microsc. Res. Tech. 1994, 28(4):277-285.
55. Li B., et al. Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma. Blood 2009, 114(24):5007-5015.
56. Jares-Erijman E.A., Jovin T.M. FRET imaging. Nat. Biotechnol. 2010, 21(11):1387-1395.
57. Phillips R., Ursell T., Wiggins P., Sens P. Emerging roles for lipids in shaping membrane-protein function. Nature 2000, 459(7245):379-385.
58. Dufrene Y.F., Martinez-Martin D., Medalsy I., Alsteens D., Muller D.J. Multiparametric imaging of biological systems by force-distance curve-based AFM. Nat. Methods 2013, 10(9):847-854.
59. Rico F., Gonzalez L., Casuso I., Puig-Vidal M., Scheuring S. High-speed force spectroscopy unfolds titin at the velocity of molecular dynamics simulations. Science 2013, 342(6159):741-743.